Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia. [PDF]
Ther Adv Drug SafMichot JM +10 more
europepmc +1 more source
British Journal of Haematology, EarlyView.Treatment‐related infertility is of great concern to younger long‐term survivors of acute leukaemia (AL). The literature on fertility outcomes in adult long‐term AL survivors is limited, mainly focused on stem cell transplantation or childhood leukaemia, with little information on the use of assisted reproduction technology.
Nanna N. Nielsen +10 more
wiley +1 more source
A Rare Manifestation of a Rare Disease: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Presenting As Paraneoplastic Aseptic Meningitis. [PDF]
CureusSaripalli A, Deemer E, Fox K.
europepmc +1 more source
British Journal of Haematology, EarlyView.Summary Infectious complications after high‐dose therapy and autologous stem cell transplantation (HDT‐ASCT) for lymphoma are the leading cause of late non‐relapse mortality. Characterizing the risk of infectious complications over time is important for rational follow‐up and because alternatives to HDT‐ASCT exist for some patients.
Freja Tang Severinsen +11 more
wiley +1 more source
Histiocytic Sarcoma Arising in a Background of Nodular Lymphocyte Predominant Hodgkin Lymphoma. [PDF]
Case Rep HematolWymer GEY, Ferra S, Naeem M.
europepmc +1 more source
A centralized radiation oncological review of cross-sectional imaging of early and intermediate stages of Hodgkin’s disease leads to significant changes of the required involved field — final analysis of a quality assurance program of the German Hodgkin study group (GHSG) on 2611 patients [PDF]
, 2003 Hans Theodor Eich +10 more
openalex +1 more source
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
Cancer, 2003 A. Younes +11 more
semanticscholar +1 more source
British Journal of Haematology, EarlyView.Efficacy of chimeric antigen receptor (CAR) T‐cell therapy depends not only on tumour traits but also on the potency of CAR‐T cells. In clinical practice, the degrees of cell proliferation during CAR‐T‐cell manufacturing vary significantly among individual cases.
Tomoyasu Jo +10 more
wiley +1 more source
Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis. [PDF]
Leuk Res RepWitkowska M +6 more
europepmc +1 more source
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival [PDF]
, 2003 Bei Zheng +8 more
openalex +1 more source